TY - JOUR
T1 - Anti-tumor necrosis factor-a treatment with infliximab for disseminated granuloma annulare
AU - Murdaca, Giuseppe
AU - Colombo, Barbara Maria
AU - Barabino, Gianfranco
AU - Caiti, Matteo
AU - Cagnati, Paola
AU - Puppo, Francesco
PY - 2010
Y1 - 2010
N2 - Granuloma annulare (GA) is a chronic inflammatory disease of unknown etiology characterized by the development of plaques preferentially localized to the distal extremities. Spontaneous remission and relapses are quite common and the course of GA is not easy to predict. Moreover, most therapeutic regimens have been used anecdotally and with variable success. We report the case of a 62-year-old White female patient affected by disseminated GA unsuccessfully treated with psoralen plus UVA photochemotherapy, prednisone, and cyclosporine (ciclosporin) who responded to the anti-tumor necrosis factor-a monoclonal antibody infliximab administered intravenously at a dosage of 5mg/kg at weeks 0, 2, and 6 and thereafter at monthly intervals for 10 additional months. Most of the GA lesions improved within 8 weeks and then slowly resolved within 10 months of treatment. We suggest that infliximab may be proposed as an additional therapeutic option in the treatment of recalcitrant forms of disseminated GA.
AB - Granuloma annulare (GA) is a chronic inflammatory disease of unknown etiology characterized by the development of plaques preferentially localized to the distal extremities. Spontaneous remission and relapses are quite common and the course of GA is not easy to predict. Moreover, most therapeutic regimens have been used anecdotally and with variable success. We report the case of a 62-year-old White female patient affected by disseminated GA unsuccessfully treated with psoralen plus UVA photochemotherapy, prednisone, and cyclosporine (ciclosporin) who responded to the anti-tumor necrosis factor-a monoclonal antibody infliximab administered intravenously at a dosage of 5mg/kg at weeks 0, 2, and 6 and thereafter at monthly intervals for 10 additional months. Most of the GA lesions improved within 8 weeks and then slowly resolved within 10 months of treatment. We suggest that infliximab may be proposed as an additional therapeutic option in the treatment of recalcitrant forms of disseminated GA.
UR - http://www.scopus.com/inward/record.url?scp=79952116693&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952116693&partnerID=8YFLogxK
U2 - 10.2165/11311040-000000000-00000
DO - 10.2165/11311040-000000000-00000
M3 - Article
C2 - 20515080
AN - SCOPUS:79952116693
VL - 11
SP - 437
EP - 439
JO - American Journal of Clinical Dermatology
JF - American Journal of Clinical Dermatology
SN - 1175-0561
IS - 6
ER -